• 

  U.S. Senate Passes Act Tripling Funding to State and Local Dementia Programs
• 

  Diagnostic Drama: Clinicians Argue Dueling Definitions of Alzheimer’s
• 

  How Bad Is Fraud in Alzheimer’s Research? Q&A With Neurologist-Sleuth Matthew Schrag
• 

  The Brain’s Blood Vessels May Be Driving Cognitive Decline in Women
• 

  Alzheimer’s Treatment Plot Twist: When (Healthy) Amyloid Goes Up, Cognitive Decline Slows Down
• 

  Cassava Drug Simufilam Fails First Phase 3 Trial, Halts Second Phase 3 Trial
• 

  Vaping Linked to Cognitive Impairment in College Students
• 

  Keeping an Eye on Vision Could Help ID Dementia Early—And Help Prevent It
• 

  One Year In, 5 Things We’ve Learned From Patients on Leqembi
• 

  A Round-up of Alzheimer’s Drug Trials News From CTAD 2024
• 

  UK Insurance Didn’t Want to Cover Leqembi. Now, It Says It Won’t Cover Kisunla, Either
• 

  CTAD: Leqembi’s Origin Story, 30 Years Ago in Arctic Sweden
• 

  8/11 of the Doctors Who Advised on Kisunla Approval Had Conflicts of Interest
• 

  After Cassava Fraud Indictment, Questioning the Ethics of Simufilam Trial
• 

  FDA-Approved Zunveyl for Alzheimer’s Symptoms On the Way in 2025

Previous121314Next